Skip to content
Back to outputs

Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998

Research output: Contribution to journalArticle

Standard

Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998. / Yu, Chengyin; Liu, Gangyi; Liu, Xiaohui; Liu, Haiming; Zheng, Hongchao; Gorecki, Darek; Patel, Asmita Vithaldas; Yu, Chen; Wang, Yiping.

In: Acta Pharmacologica Sinica, 12.04.2018.

Research output: Contribution to journalArticle

Harvard

Yu, C, Liu, G, Liu, X, Liu, H, Zheng, H, Gorecki, D, Patel, AV, Yu, C & Wang, Y 2018, 'Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998' Acta Pharmacologica Sinica.

APA

Yu, C., Liu, G., Liu, X., Liu, H., Zheng, H., Gorecki, D., ... Wang, Y. (2018). Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998. Acta Pharmacologica Sinica.

Vancouver

Yu C, Liu G, Liu X, Liu H, Zheng H, Gorecki D et al. Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998. Acta Pharmacologica Sinica. 2018 Apr 12.

Author

Yu, Chengyin ; Liu, Gangyi ; Liu, Xiaohui ; Liu, Haiming ; Zheng, Hongchao ; Gorecki, Darek ; Patel, Asmita Vithaldas ; Yu, Chen ; Wang, Yiping. / Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998. In: Acta Pharmacologica Sinica. 2018

Bibtex

@article{f35fb0fd4584475fbd7a569710d57f02,
title = "Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998",
abstract = "Aims - The objective of this study was to investigate the effect of a berberine derivative, berberine8998, on serum cholesterol and lipid levels in-vivo and to explore the mechanisms involved.Methods - Lipid lowering effect of berberine and berberine8998 was determined by high fat diet model on hamsters. Total cholesterol, low-density lipoprotein and triglycerides were analyzed. The potential target proteins on hamster liver were screened by iTRAQ labeled proteomics. The effect of berberine and berberine8998 on ACOX1 and ACSL1 was determined by western blot. Non-esterified fatty acids were analyzed to demonstrate its effect on triglyceride and fatty acid. Pharmacokinetics of berberine 8998 was conducted on SD rats.Results - Berberine8998 significant lowered the total cholesterol, triglycerides (TG) and LDL-c levels in hamsters. Bioinformatics revealed that berberine and berberine8998 shared similar metabolic pathways where fatty acid metabolism was the most dominant one. Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), Long-chain-fatty-acid—CoA ligase 1 (ACSL1) a protein involved in fatty acid metabolism, expressed differently in berberine8998 group comparing with both model group and berberine treatment group. Further biochemistry results showed that berberine8998 significantly lowered the non-esterified fatty acid (NEFA), which may lead to the reduction of TG levels in berberine8998 treatment groups and the difference in proteomics. Pharmacokinetic study showed that berberine8998, could remarkably improve absorption by 6.7 times, comparing with berberine.Conclusion - These findings suggest that berberine8998 lowers both cholesterol and lipid with different mechanisms from berberine and is a promising therapeutic candidate for treating hypercholesterolemia and obesity.",
author = "Chengyin Yu and Gangyi Liu and Xiaohui Liu and Haiming Liu and Hongchao Zheng and Darek Gorecki and Patel, {Asmita Vithaldas} and Chen Yu and Yiping Wang",
year = "2018",
month = "4",
day = "12",
language = "English",
journal = "Acta Pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Proteomics reveals potential new target protein for lipid-lowering effect of Berberine8998

AU - Yu,Chengyin

AU - Liu,Gangyi

AU - Liu,Xiaohui

AU - Liu,Haiming

AU - Zheng,Hongchao

AU - Gorecki,Darek

AU - Patel,Asmita Vithaldas

AU - Yu,Chen

AU - Wang,Yiping

PY - 2018/4/12

Y1 - 2018/4/12

N2 - Aims - The objective of this study was to investigate the effect of a berberine derivative, berberine8998, on serum cholesterol and lipid levels in-vivo and to explore the mechanisms involved.Methods - Lipid lowering effect of berberine and berberine8998 was determined by high fat diet model on hamsters. Total cholesterol, low-density lipoprotein and triglycerides were analyzed. The potential target proteins on hamster liver were screened by iTRAQ labeled proteomics. The effect of berberine and berberine8998 on ACOX1 and ACSL1 was determined by western blot. Non-esterified fatty acids were analyzed to demonstrate its effect on triglyceride and fatty acid. Pharmacokinetics of berberine 8998 was conducted on SD rats.Results - Berberine8998 significant lowered the total cholesterol, triglycerides (TG) and LDL-c levels in hamsters. Bioinformatics revealed that berberine and berberine8998 shared similar metabolic pathways where fatty acid metabolism was the most dominant one. Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), Long-chain-fatty-acid—CoA ligase 1 (ACSL1) a protein involved in fatty acid metabolism, expressed differently in berberine8998 group comparing with both model group and berberine treatment group. Further biochemistry results showed that berberine8998 significantly lowered the non-esterified fatty acid (NEFA), which may lead to the reduction of TG levels in berberine8998 treatment groups and the difference in proteomics. Pharmacokinetic study showed that berberine8998, could remarkably improve absorption by 6.7 times, comparing with berberine.Conclusion - These findings suggest that berberine8998 lowers both cholesterol and lipid with different mechanisms from berberine and is a promising therapeutic candidate for treating hypercholesterolemia and obesity.

AB - Aims - The objective of this study was to investigate the effect of a berberine derivative, berberine8998, on serum cholesterol and lipid levels in-vivo and to explore the mechanisms involved.Methods - Lipid lowering effect of berberine and berberine8998 was determined by high fat diet model on hamsters. Total cholesterol, low-density lipoprotein and triglycerides were analyzed. The potential target proteins on hamster liver were screened by iTRAQ labeled proteomics. The effect of berberine and berberine8998 on ACOX1 and ACSL1 was determined by western blot. Non-esterified fatty acids were analyzed to demonstrate its effect on triglyceride and fatty acid. Pharmacokinetics of berberine 8998 was conducted on SD rats.Results - Berberine8998 significant lowered the total cholesterol, triglycerides (TG) and LDL-c levels in hamsters. Bioinformatics revealed that berberine and berberine8998 shared similar metabolic pathways where fatty acid metabolism was the most dominant one. Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), Long-chain-fatty-acid—CoA ligase 1 (ACSL1) a protein involved in fatty acid metabolism, expressed differently in berberine8998 group comparing with both model group and berberine treatment group. Further biochemistry results showed that berberine8998 significantly lowered the non-esterified fatty acid (NEFA), which may lead to the reduction of TG levels in berberine8998 treatment groups and the difference in proteomics. Pharmacokinetic study showed that berberine8998, could remarkably improve absorption by 6.7 times, comparing with berberine.Conclusion - These findings suggest that berberine8998 lowers both cholesterol and lipid with different mechanisms from berberine and is a promising therapeutic candidate for treating hypercholesterolemia and obesity.

UR - https://www.nature.com/aps/

M3 - Article

JO - Acta Pharmacologica Sinica

T2 - Acta Pharmacologica Sinica

JF - Acta Pharmacologica Sinica

SN - 1671-4083

ER -

ID: 8846637